ATE394117T1 - Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen - Google Patents

Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen

Info

Publication number
ATE394117T1
ATE394117T1 AT03812076T AT03812076T ATE394117T1 AT E394117 T1 ATE394117 T1 AT E394117T1 AT 03812076 T AT03812076 T AT 03812076T AT 03812076 T AT03812076 T AT 03812076T AT E394117 T1 ATE394117 T1 AT E394117T1
Authority
AT
Austria
Prior art keywords
liver disease
treat liver
mutants
chemokine ccl5
rantes mutants
Prior art date
Application number
AT03812076T
Other languages
English (en)
Inventor
Amanda Proudfoot
Maureen Ajuebor
Mark Swain
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE394117T1 publication Critical patent/ATE394117T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03812076T 2002-12-23 2003-12-22 Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen ATE394117T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02102885 2002-12-23
EP03077237 2003-07-17

Publications (1)

Publication Number Publication Date
ATE394117T1 true ATE394117T1 (de) 2008-05-15

Family

ID=32715005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03812076T ATE394117T1 (de) 2002-12-23 2003-12-22 Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen

Country Status (10)

Country Link
US (1) US7476381B2 (de)
EP (1) EP1575608B1 (de)
JP (1) JP2006514699A (de)
AT (1) ATE394117T1 (de)
AU (1) AU2003302755B2 (de)
CA (1) CA2507008A1 (de)
DE (1) DE60320848D1 (de)
ES (1) ES2305573T3 (de)
NO (1) NO20053364L (de)
WO (1) WO2004062688A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007051781A1 (en) * 2005-10-31 2007-05-10 Laboratoires Serono S.A. Novel cxc-chemokine antagonists
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
ES2453592T3 (es) 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
US8632982B2 (en) * 2009-05-21 2014-01-21 Institute For Systems Biology Biomarkers for liver injury
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
AU4561497A (en) 1996-09-25 1998-04-17 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
AU2001292301A1 (en) * 2000-10-11 2002-04-22 Daiichi Pharmaceutical Co., Ltd. Novel drugs for liver diseases
EP1458756B1 (de) * 2001-12-17 2009-01-28 Laboratoires Serono SA Chemokine mutanten, die als chemokine antagonisten wirken

Also Published As

Publication number Publication date
EP1575608A2 (de) 2005-09-21
JP2006514699A (ja) 2006-05-11
DE60320848D1 (de) 2008-06-19
ES2305573T3 (es) 2008-11-01
NO20053364D0 (no) 2005-07-11
NO20053364L (no) 2005-07-11
EP1575608B1 (de) 2008-05-07
AU2003302755B2 (en) 2009-01-08
AU2003302755A1 (en) 2004-08-10
US20060228327A1 (en) 2006-10-12
US7476381B2 (en) 2009-01-13
CA2507008A1 (en) 2004-07-29
WO2004062688A2 (en) 2004-07-29
WO2004062688A3 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
DK0674641T3 (da) Pyrrolopyrimidiner som CRF-antagonister
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE60234778D1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
EA200100103A1 (ru) Ингибиторы адгезии клеток
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
RU94002482A (ru) Пятичленные гетероциклы, смесь их изомеров или отдельные изомеры и их соли
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
EA200201214A1 (ru) Замещенные тиоацетамиды
TR199802385T2 (xx) TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
EA200500856A1 (ru) Новые химические соединения
FI971756A0 (fi) CD23:een sitoutuvia aineita
ATE346041T1 (de) N-hydroxyformamid-derivate
SE0302304D0 (sv) Novel compounds
EA200100342A1 (ru) Связывающие соединения адгезионной молекулы нервной клетки
WO2004024064A8 (en) Compositions and methods for the diagnosis and treatment of tumor
ATE394117T1 (de) Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
ATE421974T1 (de) Chemokine mutanten, die als chemokine antagonisten wirken
MX2007000046A (es) Compuestos, composiciones y metodos de imidazolo relacionados para su uso.
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties